FDA Decision on Tradipitant New Drug Application Refusal

The FDA has issued a final agency decision to refuse approval of the New Drug Application (NDA) for Tradipitant. This decision follows a proposal to refuse approval and is based on confidential business information. A redacted version of the agency decision document is available for review.

This action signifies a definitive rejection of the Tradipitant NDA by the FDA. Drug manufacturers seeking approval for new therapies should note this outcome and understand that the agency's decision, even if based on confidential information, has significant implications for the applicant. While specific actions for other entities are not mandated by this document, it serves as a case study in the FDA's drug approval and enforcement processes, highlighting the potential for application refusal.